As both conventional AM and UAM have been found to harbor BRAF p.V600E mutations, aggressive and destructive tumors could be candidates for BRAF-targeted therapy that has the potential to reduce tumor size and ultimately enable a conservative surgical procedure. Here, BRAF is linked to neoplasm.